Domača stran4DX • ASX
4DMedical Ltd
0,60 $
28. jan., 07:36:37 GMT +11 · AUD · ASX · Izjava
DelnicaVrednostni papir, ki kotira v AU
Prejšnji trg. dan.
0,56 $
Dnevni razpon
0,59 $ - 0,63 $
Letni razpon
0,41 $ - 0,83 $
Tržna kapitalizacija
250,69 mio. AUD
Povprečni obseg
904,84 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
ASX
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
(AUD)jun. 2024Sprememba L/L
Prihodek
1,48 mio.1.172,70 %
Stroški poslovanja
12,56 mio.11,42 %
Čisti dohodek
−10,19 mio.−33,78 %
Čista dobičkovnost prihodkov
−687,8489,49 %
Earnings per share
EBITDA
−11,09 mio.−5,51 %
Efektivna davčna stopnja
−0,01 %
Skupna sredstva
Skupne obveznosti
(AUD)jun. 2024Sprememba L/L
Denar. in kratkor. naložbe
30,61 mio.−56,01 %
Skupna sredstva
120,02 mio.29,16 %
Skupne obveznosti
49,09 mio.128,71 %
Celoten lastniški kapital
70,93 mio.
Shares outstanding
410,53 mio.
Razmerje P/B
3,32
Donosnost sredstev
−23,28 %
Donosnost kapitala
−36,73 %
Neto sprememba denarnih sredstev
(AUD)jun. 2024Sprememba L/L
Čisti dohodek
−10,19 mio.−33,78 %
Denar iz dejavnosti
−8,06 mio.8,54 %
Denar iz naložb
−339,48 tis.−21,29 %
Denar iz financiranja
−233,98 tis.−101,11 %
Neto sprememba denarnih sredstev
−8,64 mio.−172,48 %
Prost denarni tok
−5,43 mio.13,25 %
Vizitka
4DMedical is a medical technology company, based in Australia and the United States. 4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report. 4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
Generalni direktor
Datum ustanovitve
2013
Spletno mesto
Zaposleni
145
Iskanje
Počisti iskanje
Zapiranje iskanja
Googlove aplikacije
Glavni meni